Rafferty Asset Management
ITOS

Rafferty Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Rafferty Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-49,835
Closed -$509K – 1160
2024
Q3 		$509K Buy
49,835
+13,850
+38% +$211K ﹤0.01% 925
2024
Q2 		$534K Buy
+35,985
New +$516K ﹤0.01% 930
2023
Q4 		– Sell
-85,189
Closed -$933K – 1085
2023
Q3 		$933K Sell
85,189
-1,409
-2% -$18K 0.01% 808
2023
Q2 		$1.15M Sell
86,598
-27,452
-24% -$391K 0.01% 787
2023
Q1 		$1.55M Buy
114,050
+11,384
+11% +$204K 0.01% 682
2022
Q4 		$2.01M Sell
102,666
-23,435
-19% -$458K 0.02% 579
2022
Q3 		$2.4M Buy
126,101
+26,733
+27% +$616K 0.03% 466
2022
Q2 		$2.05M Buy
99,368
+2,067
+2% +$49K 0.02% 456
2022
Q1 		$3.13M Buy
97,301
+56,985
+141% +$2.07M 0.02% 505
2021
Q4 		$1.88M Buy
+40,316
New +$1.34M 0.01% 686
2021
Q2 		– Sell
-27,221
Closed -$930K – 1261
2021
Q1 		$930K Buy
+27,221
New +$984K 0.01% 787

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Rafferty Asset Management's ITOS Position: Q4 2024 in Review

Rafferty Asset Management sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 49,835 shares — an estimated $509K sold.

Rafferty Asset Management first reported a position in ITOS in Q1 2021 and held it in 11 quarters. The position peaked at $3.13M in Q1 2022. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Rafferty Asset Management reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 49,835 iTeos Therapeutics shares in Q4 2024, an estimated $509K.
  • Rafferty Asset Management first reported a position in iTeos Therapeutics in Q1 2021 and held it in 11 quarters.
  • Rafferty Asset Management's iTeos Therapeutics position peaked at $3.13M in Q1 2022.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Rafferty Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.